Chimeric antigen receptor (CAR) T cell therapy is a form of T cell engineering where T cells are obtained from a patient and engineered in a laboratory to better kill the patient's cancer cells. Specifically, CAR T cells are modified to express a receptor on their surface that recognizes the specific antigen present on the patient's cancer cells.
-
Date: April 06, 2021 Time: 8:00am (PST), 11:00am (EST) The discovery of the reproducibility crisis has called into question a worrying number of scientific results over the last few years. In...
Date: March 31, 2021 Time: 08:00am PST CytoFLEX SRT has enabled researcher lead self-service sorting. The need for a cell sorting expert to setup and maintain the sorter status is now necess...
DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
Date: February 10, 2021 Time: 8:00am (PST), 11:00am (EST) Uncovering the interactions between the immune system and cancer cells or pathogens is key for understanding and controlling both ca...
Date: February 3, 2021 Time: 8:00am (PST), 11:00am (EST) This introduction webinar will provide you with an overview of the general immuno-oncology (IO) research field...
Date: November 17, 2020 Time: 8:00am COVID-19 is a complex pathological condition caused by infection with SARS-CoV. Different features have been observed in patients with a severe dis...
DATE: November 5, 2020 TIME: 9:00am (PDT), 12:00pm (EDT) With accelerating development and approval of cell therapies, biologic drugs, and antiviral treatments comes a need for more robust a...
DATE: November 4th, 2020 TIME: 11:00am PST As cell therapies become more complex, the need for robust analytical tools to characterize such products as they enter the clinic has increased in...
B cells and tertiary lymphoid structures (TLS) promote immunotherapy response 1:00–1:30 pm PDT Presented By: Rafet Basar, MD...
On measuring photons and ions: Impact on panel design, signal detection and data quality 10:30–11:00 am PDT Presented By: Tim Bushnell, PhD, MBA Monitoring immunotherapy with a mass cy...
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...
DATE: June 23, 2020 TIME: 6:00 am PDT, 9:00 am EDT In this webinar for scientists and researchers, Rama Shivakumar, a senior scientist at MaxCyte Inc., will highlight powerful case studies t...
B7-H3 is actively being explored as an immunotherapy target for pediatric patients with solid tumors using monoclonal antibodies or T cells expressing chimeric antigen receptors (CARs). B7-H...